Amylyx Pharmaceuticals (AMLX) vs Arcutis Biotherapeutics (ARQT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 103.3% versus a gain of 17.5%. Amylyx Pharmaceuticals is the larger company by market cap ($3.39 billion vs $3.04 billion), about 1.1 times the size, while Arcutis Biotherapeutics is growing revenue faster (+91.3% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | ARQT |
|---|---|---|
| Share price | $27.03 | $24.18 |
| Market cap | $3.39B | $3.04B |
| 1-day change | -1.46% | +0.04% |
| YTD return | +127.07% | -16.77% |
| 1-year return | +103.34% | +17.50% |
| 5-year return | — | +8.48% |
| P/E ratio (TTM) | — | 109.91 |
| Forward P/E | — | 17.78 |
| EPS (TTM) | $-1.41 | $0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $376.07M |
| Revenue growth (YoY) | -100.00% | +91.34% |
| Net income (latest FY) | $-144.74M | $-16.14M |
| Gross margin | — | 90.24% |
| Operating margin | — | -3.25% |
| Net margin | — | -4.29% |
| 52-week high | $41.14 | $31.77 |
| 52-week low | $10.83 | $19.30 |
| Distance from 52-week high | -34.30% | -23.89% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +56.71% | +53.02% |
| Average volume | 2.33M | 2.22M |
| Shares outstanding | 125.51M | 125.69M |
| Employees | 136 | 354 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed ARQT by 85.8 percentage points over the past year.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
AMLX vs ARQT FAQ
Which is bigger, Amylyx Pharmaceuticals or Arcutis Biotherapeutics?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.39B compared with $3.04B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, AMLX or ARQT?
AMLX returned +103.34% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Arcutis Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.